Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial

BACKGROUND: Traditional systemic immunosuppressants and advanced therapies improve signs and symptoms of moderate-to-severe atopic dermatitis (AD). However, data are limited in severe and/or difficult-to-treat AD. In the phase 3 JADE COMPARE trial of patients with moderate-to-severe AD receiving bac...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, Eric L., Silverberg, Jonathan I., Thyssen, Jacob P., Viguier, Manuelle, Thaçi, Diamant, de Bruin-Weller, Marjolein, Weidinger, Stephan, Chan, Gary, DiBonaventura, Marco, Biswas, Pinaki, Feeney, Claire, Koulias, Christopher, Cork, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293387/
https://www.ncbi.nlm.nih.gov/pubmed/37213005
http://dx.doi.org/10.1007/s40257-023-00785-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293387/
https://www.ncbi.nlm.nih.gov/pubmed/37213005
http://dx.doi.org/10.1007/s40257-023-00785-5

Ejemplares similares